AN2 Therapeutics, Inc. (ANTX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$29.83M | +39.4% |
| 2024 | -$49.26M | +7.6% |
| 2023 | -$53.29M | -59.2% |
| 2022 | -$33.46M | -63.4% |
| 2021 | -$20.48M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$29.83M | +39.4% |
| 2024 | -$49.26M | +7.6% |
| 2023 | -$53.29M | -59.2% |
| 2022 | -$33.46M | -63.4% |
| 2021 | -$20.48M | — |